Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.

Bristol Myers Squibb faces additional patent cliffs in the next few years, creating a near-term revenue headwind. The article suggests newer drugs and a deep pipeline could help offset the loss of exclusivity, but the overall message remains cautious. No specific financial figures or guidance changes were provided.

Analysis

Bristol Myers Squibb faces additional patent cliffs in the next few years, creating a near-term revenue headwind. The article suggests newer drugs and a deep pipeline could help offset the loss of exclusivity, but the overall message remains cautious. No specific financial figures or guidance changes were provided.